A Study to Learn About a Vaccine Against E Coli in Healthy Adults
NCT ID: NCT07122986
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
310 participants
INTERVENTIONAL
2025-08-11
2028-05-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
Phase 1 Study of dmLT ID Vaccination in Healthy Adults
NCT02531685
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
NCT03170609
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
NCT03548064
Clinical Trial of Recombinant Hepatitis E Vaccine
NCT01014845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
E coli vaccine 1 Dose A
Candidate E coli vaccine on day 1 and day 180
E coli vaccine 1 Dose A
Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval
E coli vaccine 1 Dose B
Candidate E coli vaccine on day 1 and day 180
E coli vaccine 1 Dose B
Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval
E coli vaccine 2
Candidate E coli vaccine on day 1 and day 180
E coli vaccine 2
Candidate E coli vaccine 2, administered according to a 0, 6-month interval
E coli vaccine 3
Candidate E coli vaccine on day 1 and day 180
E coli vaccine 3
Candidate E coli vaccine 3, administered according to a 0, 6-month interval
E coli Vaccine 4 Dose A
Candidate E coli vaccine on day 1 and day 180
E coli Vaccine 4 Dose A
Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval
E coli Vaccine 4 Dose B
Candidate E coli vaccine on day 1 and day 180
E coli Vaccine 4 Dose B
Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval
E coli Vaccine 4 Dose C
Candidate E coli vaccine on day 1 and day 180
E coli Vaccine 4 Dose C
Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval
E coli Vaccine 5 Dose A
E coli Vaccine 5 Dose A
Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval
E coli Vaccine 5 Dose B
E coli Vaccine 5 Dose B
Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval
Placebo
Placebo received on day 1 and day 180
Placebo
Placebo administered according to a 0, 6-month interval
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E coli vaccine 1 Dose A
Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval
E coli vaccine 1 Dose B
Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval
E coli vaccine 2
Candidate E coli vaccine 2, administered according to a 0, 6-month interval
E coli vaccine 3
Candidate E coli vaccine 3, administered according to a 0, 6-month interval
E coli Vaccine 4 Dose A
Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval
E coli Vaccine 4 Dose B
Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval
E coli Vaccine 4 Dose C
Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval
E coli Vaccine 5 Dose A
Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval
E coli Vaccine 5 Dose B
Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval
Placebo
Placebo administered according to a 0, 6-month interval
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy participants as determined by medical history, physical examination, and clinical judgement of the investigator to be eligible for inclusion in the study.
Exclusion Criteria
2. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
3. Women who are pregnant, plan to become pregnant during the study, or are breastfeeding.
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Orange County Research Center
Lake Forest, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Miami Eye Institute
Hollywood, Florida, United States
Research Centers of America
Hollywood, Florida, United States
NYU Langone Health
New York, New York, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Senders Pediatrics
South Euclid, Ohio, United States
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, United States
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, United States
University Eye Specialists, P.C. (Ophthalmologist)
Maryville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C5211001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.